Bharat Biotech

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by John B123 (talk | contribs) at 15:53, 3 July 2020 (Undid revision 965723310 by Amkgp (talk) You can't simply remove tag because you don't like them). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Bharat Biotech Limited
Company typePrivate Limited Company
IndustryPharmaceuticals
Founded1996
HeadquartersHyderabad, India
Key people
Dr. Krishna M. Ella
ProductsROTAVAC[1], TypbarTCV[2], Biopolio, Comvac and JENVAC
SubsidiariesChiron Behring Vaccines [3]
Websitewww.bharatbiotech.com

Bharat Biotech Limited or Bharat Biotech International Limited is a Pharmaceuticals company headquartered at Hyderabad, India engaged in manufacturing innovative vaccines and bio-therapeutics.[4]

Overview

Bharat Biotech has its manufacturing facility situated at Genome Valley, Hyderabad, India.[5] Currently, the company employs over 700 employees.[4] The company has a presence in over 65 countries and works on making affordable medicines accessible to patients worldwide.[4]

The company has reported to have delivered around 3 billion vaccine doses throughout the world.[4] Some of the breakthroughs include development of Eco-friendly recombinant[6] Hepatitis B and a naturally attenuated strain derived Rotavirus vaccine called ROTAVAC[7][8] They were one of the first to develop vaccines for viral diseases like Chikungunya[9][10] and Zika.[11][12]. They also produces vaccines for Japanese Encephalitis.[13]

COVID-19 vaccine development

In April 2020, the company announced that they have partnered with US-based company FluGen and University of Wisconsin-Madison to develop a COVID-19 vaccine.[14][15]

In May 2020, ICMR - National Institute of Virology approved and provided the virus strains for developing a fully indigenous COVID-19 vaccine.[16][17]. On June 29, the company got permission to conduct human trials of developmental COVID-19 vaccine named Covaxin, from DCGI, Government of India after successful phase-I and II clinical trials.[18][19][20][21]

See also

Reference

  1. ^ "WHO prequalifies new rotavirus vaccine". WHO. Retrieved 2 July 2020.
  2. ^ "WHO recommends use of first typhoid conjugate vaccine". WHO. Retrieved 2 July 2020.
  3. ^ Bureau, Our. "Bharat Biotech buys Chiron Behring Vaccines from GSK". The Hindu BusinessLine. Retrieved 1 July 2020.
  4. ^ a b c d "Leading Biotech Vaccine Manufacturers in India - Bharat Biotech". www.bharatbiotech.com. Retrieved 30 June 2020.
  5. ^ "Bacteriology Lab | Virology Lab in India | Bharat Biotech". www.bharatbiotech.com.
  6. ^ "Process for the preparation and purification of recombinant proteins". patents.google.com. US patent No US8956812B2. 23 August 2004.
  7. ^ Bhandari, Nita; Rongsen-Chandola, Temsunaro; Bavdekar, Ashish; John, Jacob; Antony, Kalpana; Taneja, Sunita; Goyal, Nidhi; Kawade, Anand; Kang, Gagandeep; Rathore, Sudeep Singh; Juvekar, Sanjay; Muliyil, Jayaprakash; Arya, Alok; Shaikh, Hanif; Abraham, Vinod; Vrati, Sudhanshu; Proschan, Michael; Kohberger, Robert; Thiry, Georges; Glass, Roger; Greenberg, Harry B; Curlin, George; Mohan, Krishna; Harshavardhan, G V J A; Prasad, Sai; Rao, T S; Boslego, John; Bhan, Maharaj Kishan (June 2014). "Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial". The Lancet. 383 (9935): 2136–2143. doi:10.1016/S0140-6736(13)62630-6. PMID 24629994.
  8. ^ Kang, G (October 2006). "Rotavirus vaccines". Indian journal of medical microbiology. 24 (4): 252–7. doi:10.4103/0255-0857.29382. PMID 17185842.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  9. ^ "Bharat Biotech's Zika, Chikungunya vaccines to enter Phase II trials; focus now on private label market". Moneycontrol.
  10. ^ "CEPI, 치쿤구니아 백신 개발 위해 국제백신연구소-바라트 바이오텍 컨소시엄에 최대 1410만달러 지원". CEPI, 치쿤구니아 백신 개발 위해 국제백신연구소-바라트 바이오텍 컨소시엄에 최대 1410만달러 지원 - 뉴스와이어 (in Korean). 3 June 2020.
  11. ^ "Bharat Biotech gets breakthrough in developing Zika vaccine". The Economic Times. 4 February 2016.
  12. ^ "CEPI awards up to US$14.1million to consortium of IVI and Bharat Biotech to advance development of Chikungunya vaccine in collaboration with Ind-CEPI – IVI". www.ivi.int. International Vaccine Institute. Retrieved 30 June 2020.
  13. ^ Singh, Anit; Mitra, Monjori; Sampath, Gadey; Venugopal, P.; Rao, J. Venkateswara; Krishnamurthy, B.; Gupta, Mukesh Kumar; Sri Krishna, S.; Sudhakar, B.; Rao, N. Bhuvaneswara; Kaushik, Yashpal; Gopinathan, K.; Hegde, Nagendra R.; Gore, Milind M.; Krishna Mohan, V.; Ella, Krishna M. (1 September 2015). "A Japanese Encephalitis Vaccine From India Induces Durable and Cross-protective Immunity Against Temporally and Spatially Wide-ranging Global Field Strains". Journal of Infectious Diseases. 212 (5): 715–725. doi:10.1093/infdis/jiv023.
  14. ^ "UW-Madison, Flugen, Bharat Biotech to develop coroflu, a coronavirus vaccine". Global Health Institute. Retrieved 30 June 2020.
  15. ^ "Bharat Biotech ties up with US varsity for Covid vaccine". Hindustan Times. 20 May 2020.
  16. ^ "ICMR teams up with Bharat Biotech to develop Covid-19 vaccine". Livemint. 9 May 2020.
  17. ^ Chakrabarti, Angana (10 May 2020). "India to develop 'fully indigenous' Covid vaccine as ICMR partners with Bharat Biotech". ThePrint.
  18. ^ "India's First COVID-19 Vaccine Candidate Approved for Human Trials". The New York Times. 29 June 2020.
  19. ^ "Human trial of India coronavirus vaccine announced". BBC News. 30 June 2020.
  20. ^ "Bharat Biotech's Covid vaccine 1st in India to get approval for human trials". The Indian Express. 30 June 2020.
  21. ^ "Covaxin: India's first COVID19 vaccine candidate from Bharat Biotech to begin human trials; check details". The Financial Express. 30 June 2020.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Bharat_Biotech&oldid=965817173"